A model of upper airway obstruction will be used to test the hypothesis that HELIOX 21 when additional oxygen is added (which is a common clinical situation) still can reduce the work of breathing. To test this hypothesis healty subjects will breath Heliox with additional oxygen for 2 minutes each through a resistive load.
Conditions
Interventions
Trade Name: HELIOX21
Product Name: HELIOX21
Pharmaceutical Form: Inhalation gas
Other descriptive name: Oxygen
Concentration unit: % percent
Concentration number: 25-75
Pharmaceutical form of the plac
Sponsors
University Witten/Herdecke
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Healthy volunteers Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Any condition that renders the subject "not healthy". To exclude preganant women only subjects will be tested that demonstrate a negative pregnancy test on the day of study participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Test the hypothesis that HELIOX with lower Helium content still can reduce the work of breathing.;Secondary Objective: ;Primary end point(s): Measurement of heart rate, blood pressure (noninvasively using Finapress) and stroke volume (using noninvasive impedance thoracocardiography) that all show cyclic changes during loaded breathing and the reduction of these cyclic changes when the subject breathes HELIOX in a modell of upper airway obstruction. | — |
Countries
Germany
Outcome results
None listed